XCNQ
DOSE
Market cap17mUSD
Jul 22, Last price
0.19CAD
1D
-2.56%
1Q
2.70%
IPO
-76.25%
Name
Rapid Dose Therapeutics Corp
Chart & Performance
Profile
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑02 | 2023‑02 | 2022‑02 | 2021‑02 | 2020‑02 | 2019‑02 | 2017‑09 | 2016‑09 | 2015‑09 | |
Income | |||||||||
Revenues | 1,020 42.06% | 718 -59.00% | |||||||
Cost of revenue | 3,483 | 3,619 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,463) | (2,901) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 2 | ||||||||
Tax Rate | |||||||||
NOPAT | (2,463) | (2,902) | |||||||
Net income | (4,306) 12.98% | (3,812) -69.62% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,205 | 152 | |||||||
BB yield | -6.56% | ||||||||
Debt | |||||||||
Debt current | 329 | 1,395 | |||||||
Long-term debt | 2,154 | 580 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 2,322 | 1,948 | |||||||
Cash flow | |||||||||
Cash from operating activities | (2,295) | (864) | |||||||
CAPEX | 1 | ||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 2,428 | 857 | |||||||
FCF | (2,818) | (418) | |||||||
Balance | |||||||||
Cash | 161 | 28 | |||||||
Long term investments | |||||||||
Excess cash | 110 | ||||||||
Stockholders' equity | (12,626) | (9,823) | |||||||
Invested Capital | 11,922 | 8,764 | |||||||
ROIC | |||||||||
ROCE | 349.72% | 273.92% | |||||||
EV | |||||||||
Common stock shares outstanding | 104,964 | 103,416 | |||||||
Price | 0.18 | ||||||||
Market cap | 18,369 | ||||||||
EV | 20,690 | ||||||||
EBITDA | (1,843) | (2,273) | |||||||
EV/EBITDA | |||||||||
Interest | 661 | 265 | |||||||
Interest/NOPBT |